1. Glasgow prognostic score after concurrent chemoradiotherapy is a prognostic factor in advanced head and neck cancer
- Author
-
Pei-Hung Chang, Feng-Che Kuan, Jason Chia-Hsun Hsieh, Cheng-Hsu Wang, Eric Yen-Chao Chen, Shih-Wei Yang, Wen-Chi Chou, and Kun-Yun Yeh
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Prognostic factor ,Multivariate analysis ,cachexia ,Prognostic score ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Tumor stage ,medicine ,In patient ,Glasgow prognostic score (GPS) ,Stage (cooking) ,chemoradiation ,business.industry ,Head and neck cancer ,medicine.disease ,Concurrent chemoradiotherapy ,nutrition ,030104 developmental biology ,inflammation ,030220 oncology & carcinogenesis ,Original Article ,head and neck cancer ,sense organs ,business - Abstract
Objective This study aims to evaluate the impact and potential prognostic roles of the pre- and post-treatment Glasgow prognostic score (GPS) and the change thereof in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy (CCRT). Methods We collected GPS and clinicopathological data of 139 stage III, IVA, and IVB head and neck cancer patients who underwent CCRT between 2008 and 2011. Their GPSs pre- and post-CCRT and the change thereof were analyzed for correlations with recurrence and survival. Results The GPS changed in 72 (51.8%) patients, with worse scores observed post-CCRT in 65 (90.3%) of the GPS changed patients. Patients in the improved GPS group showed a tendency toward better survival. From the multivariate analysis, the post-CCRT GPS level was an independent prognostic factor in addition to tumor stage. Conclusions After CCRT, a high GPS was revealed to be an important predictor of survival for advanced head and neck cancer.
- Published
- 2017
- Full Text
- View/download PDF